VIVUS Upgraded to Outperform by Zacks (VVUS)
VIVUS (NASDAQ:VVUS) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a report released on Tuesday. The firm currently has a $5.70 price target on the stock. Zacks‘s price target would indicate a potential upside of 7.55% from the stock’s previous close.
VIVUS (NASDAQ:VVUS) traded down 1.89% during mid-day trading on Tuesday, hitting $5.20. The stock had a trading volume of 940,585 shares. VIVUS has a 52-week low of $4.56 and a 52-week high of $15.40. The stock has a 50-day moving average of $5.07 and a 200-day moving average of $6.58. The company’s market cap is $537.2 million.
VIVUS (NASDAQ:VVUS) last announced its earnings results on Monday, May 5th. The company reported ($0.15) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.37) by $0.22. The company had revenue of $36.70 million for the quarter, compared to the consensus estimate of $11.40 million. During the same quarter last year, the company posted ($0.53) earnings per share. VIVUS’s revenue was up 792.7% compared to the same quarter last year. Analysts expect that VIVUS will post $-1.28 EPS for the current fiscal year.
A number of other analysts have also recently weighed in on VVUS. Analysts at JPMorgan Chase & Co. cut their price target on shares of VIVUS from $8.00 to $5.00 in a research note on Tuesday, May 6th. They now have a “neutral” rating on the stock. Separately, analysts at Credit Suisse cut their price target on shares of VIVUS from $7.00 to $6.00 in a research note on Tuesday, May 6th. Finally, analysts at Wells Fargo & Co. initiated coverage on shares of VIVUS in a research note on Thursday, April 24th. They set a “market perform” rating on the stock. Four investment analysts have rated the stock with a sell rating, five have given a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $7.48.
VIVUS, Inc is a biopharmaceutical company. It commercializes and develops therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health.
To view Zacks’ full report, visit Zacks’ official website.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.